Morgan Stanley initiated coverage on shares of Personalis (NASDAQ:PSNL) in a research report report published on Monday, BenzingaRatingsTable reports. The firm issued an overweight rating and a $28.00 price objective on the stock.

Separately, Bank of America set a $68.00 target price on shares of Inphi and gave the stock a buy rating in a report on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $28.25.

Shares of PSNL opened at $20.31 on Monday. Personalis has a 12 month low of $21.73 and a 12 month high of $31.88.

In other Personalis news, Director Ken Ludlum bought 70,000 shares of Personalis stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $1,190,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Read More: Diluted Earnings Per Share

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.